Sponsors (2)
The bill directs substantial new, multi‑year federal funding and several policy changes to expand opioid prevention, treatment, recovery housing, and workforce support—improving access for many in high‑burden areas—but does so at significant federal and state cost, with uneven geographic effects and added administrative and implementation complexity.
States, Tribes, and local programs receive large, multi-year federal appropriations and new grant funding that materially expand prevention, treatment, recovery housing, surveillance, and public‑health response capacity.
Medicaid enrollees with substance use disorder will face fewer coverage barriers and gain better access to care because the bill enables Medicaid-funded recovery housing, bans utilization controls for medication‑assisted treatment (MAT), and raises behavioral‑health provider reimbursement for a multi‑year period.
People at risk of opioid overdose (including Medicare and low‑income beneficiaries) will have improved access to opioid reversal agents because at least one FDA‑approved agent must be covered without deductible/coinsurance and without prior authorization.
Taxpayers and state budgets face large new and ongoing costs—hundreds of millions to billions per year—which will increase federal outlays and could crowd out or require tradeoffs with other priorities.
States, Medicaid programs, and managed‑care entities may face material fiscal pressure or financial risk (higher Medicaid costs, higher capitated payments, or uncompensated program growth) that could force cuts elsewhere or strain state budgets.
The bill's allocation rules (top‑10 state targets, heavy weighting by overdose rates, minimum per‑state set‑asides, and targeted state streams) risk uneven geographic distribution and may leave some high‑need communities or improving states without needed resources.
Based on analysis of 14 sections of legislative text.
Creates a multi‑year opioid response package: funds treatment, recovery housing demos, bans prior authorization/cost‑sharing for naloxone coverage, raises Medicaid behavioral‑health payment floors, and reauthorizes prevention grants.
Official title: Provide funding for programs and activities under the SUPPORT for Patients and Communities Act.
Introduced June 24, 2026 by Jeanne Shaheen · Last progress June 24, 2026
Provides a broad federal package to prevent and treat substance use disorders, with new demonstrations, grant programs, and multi-year appropriations focused on opioid use disorder recovery housing, treatment access, training, and community supports. It requires Medicaid and private plans to remove cost-sharing and prior authorization for overdose reversal drugs, raises Medicaid payment floors for behavioral health services for people with substance use disorder, and funds state and local prevention, treatment, and law-enforcement mental-health pilots. Creates a CMMI demonstration testing capitated Medicaid budgets to pay for recovery housing, extends selected Medicaid demonstration waivers, reauthorizes and funds many prevention and treatment programs through FY2027–FY2036, and conditions some Medicaid matching and plan rules on removing utilization controls for medication‑assisted treatment and overdose-reversal drugs. Effective dates and funding streams vary by provision, with many appropriations starting FY2027 and some statutory effective dates beginning October 1, 2026.